Phase IB/II Of CPX-351 As Maintenance Therapy In AML Patients Ineligible For Bone Marrow Transplantation Read more
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Entospletinib In Combination With Intensive Induction And Consolidation Chemotherapy In Adults With Actively Diagnosed Nucleophosmin 1-Mutated (NPM1) Acute Myeloid Leukemia Read more
A Phase 1 Trial To Evaluate The Potential Impact Of Renal Impairment On The Pharmacokinetics And Safety Of CPX-351 (Daunorubicin And Cytarabine) Liposome For Injection Treatment In Adult Patients With Hematologic Malignancies Read more
This Is A Single-Arm, Open-Label, Multicenter, Non- Randomized Interventional Study To Evaluate The Pharmacokinetic (PK) Interaction, Safety, And Preliminary Efficacy Of ASTX727 When Given In Combination With Venetoclax For The Treatment Of Actively Diagnosed Acute Myeloid Leukemia (AML) In Adults Who Are Age 75 Years Or Older, Or Who Have Comorbidities That Preclude Use Of Intensive Induction Chemotherapy. Read more
Abbvie, Protocol: M16-191, PI: Dr. Mccloskey, Title A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) Read more
Abbvie, Protocol: M20-178, PI: Dr. Mccloskey, A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy And Safety Of Navitoclax In Combination With Ruxolitinib Versus Best Available Therapy In Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) Read more
A Multi-Phase, Dose-Escalation Followed By An Open-Label, Randomized, Crossover Study Of Oral ASTX030 (Cedazuridine And Azacitidine Given In Combination) Versus Subcutaneous Azacitidine In Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Or Acute Myeloid Leukemia (AML) Read more
An Open-Label, Multicenter, Extension Study For Subjects Who Participated In Prior Clinical Studies Of ASTX727 (Standard Dose) Read more
A Phase I Multi-Dose Study Of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) In Adults With Actively Diagnosed Primary Or Secondary Acute Myeloid Leukemia (AML) In Morphologic Complete Remission With Minimal Residual Disease (MRD) Read more
